Harout Semerjian
Chief Executive Officer at GLYCOMIMETICS, INC.
Net worth: 75 000 $ as of 2024-03-30
Profile
Harout Semerjian is the President, Chief Executive Officer & Director at GlycoMimetics, Inc. He was previously the President, Chief Executive Officer & Director at Immunomedics, Inc. for a brief period in 2020.
Before that, he was the Chief Commercial Officer & Executive VP at Ipsen SA from 2018 to 2020 and the Managing Director at Ipsen Pharma SAS.
Semerjian holds an MBA from both Queen's University and Cornell University, as well as an undergraduate degree from Lebanese American University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
0.04% | 2024-03-14 | 25,000 ( 0.04% ) | 75 000 $ | 2024-03-30 |
Harout Semerjian active positions
| Companies | Position | Start |
|---|---|---|
| GLYCOMIMETICS, INC. | Chief Executive Officer | 2021-08-05 |
Former positions of Harout Semerjian
| Companies | Position | End |
|---|---|---|
| IMMUNOMEDICS, INC. | Chief Executive Officer | 2020-05-26 |
| IPSEN | Corporate Officer/Principal | 2020-03-31 |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Corporate Officer/Principal | - |
Training of Harout Semerjian
| Queen's University | Masters Business Admin |
| Cornell University | Masters Business Admin |
| Lebanese American University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| IPSEN | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Health Technology |
- Stock Market
- Insiders
- Harout Semerjian
